Active Ingredient: benzylpenicillin
- First line antibiotic
- Narrow spectrum therapy
- Negligible off – target effects
Each ml contains: benzylpenicillin (procaine) monohydrate 300 mg (corresponding to 170 mg benzylpenicillin).
Suspension for injection.
Primopen is a narrow-spectrum antibiotic that does not select for cross-resistance in non-targeted pathogens and minimizes collateral damage upon the host microbiome. It is therefore a precision antibiotic therapy with minimal off-target effects but high efficacy, when properly used. Primopen belongs to the lowest-risk category of antibiotics, and should be used as a first line treatment, whenever possible.
For the treatment of infections caused by penicillin-sensitive bacteria, such as: Glasser disease, pleuropneumonia by Actinobacillus pleuropneumoniae, necrotic enteritis, Erysipelas, clinical mastitis due to streptococci and penicillin susceptible staphylococci, metritis caused by susceptible bacteria, bacterial pneumonia by Pasteurella multocida and other susceptible bacteria, actinomycosis, strangles, orthopedic infections caused by susceptible bacteria, skin and soft tissue infections caused by susceptible organisms.
Deep intramuscular injection.
The recommended daily dose is 12 mg of benzylpenicillin procaine/kg body weight equivalent to 1 ml/25 kg body weight/day.